Ann Kramer is CEO of The Electrospinning Company. Under her leadership the SME, originally a spin-out from the Science and Technology Facilities Council, has developed a biomaterial platform with applications in regenerative medicine. It now manufactures and exports components for an American orthopaedic medical device, offers a biomaterial development service to the medical device industry and is evaluating proprietary biomaterials for wound healing and cell therapy.
Ann has a Natural Science degree from the University of Cambridge. She spent almost 20 years working in a range of techno-commercial, international roles in agritech for ICA, Zeneca and Syngenta before 15 years in leadership roles with UK SMEs including Oxitec (acquired by Intrexon), Immunocore and Biosyntha (industrial biotech). Ann was on the strategic facilities advisory board for the Royce National Institute for advanced materials innovation and is an InnovateUK Women in Innovation ambassador.